ALIPHATIC VICINAL FLUOROBROMIDES SOME PREPARATIONS AND REACTIONS
作者:F. L. M. Pattison、D. A. V. Peters、F. H. Dean
DOI:10.1139/v65-223
日期:1965.6.1
The addition of "BrF", using N-bromoamides in anhydrous hydrogen fluoride, to a number of aliphatic alkenes has been studied. As expected, the bromine atom in the resultant vicinal fluorobromides exhibited relatively low reactivity in nucleophilic and hydrogenolytic reactions.
Bromofluorination of unsaturated compounds using DMPU/HF as a fluorinating reagent
作者:Shengzong Liang、Francis J. Barrios、Otome E. Okoromoba、Zofia Hetman、Bo Xu、Gerald B. Hammond
DOI:10.1016/j.jfluchem.2017.07.016
日期:2017.11
as the fluorinatingreagent. The DMPU/HF complex showed to be an efficient fluorinatingreagent to convert alkenes into their corresponding bromofluoro compounds. It showed to have high reactivity and the process afforded bromofluorinated products with good Markovnikov regioselectivity. These fluorinated compounds are useful starting materials and serve as building blocks for many fluorinated biologically
Photolysis of Bromo- and Chloro-Substituted Benzyl Derivatives. Competition between Ionic and Radical Pathways
作者:Berta Košmrlj、Boris Šket
DOI:10.1021/jo0001481
日期:2000.10.1
solutions of tetrahydrofuran, acetonitrile, and cyclohexane. The effect of free radical inhibitor and metal hydrides on products formation as well as their ratio was analyzed to elucidate the reaction pathway. In the first step homolytic C-X bondcleavage occurs from a single excited state, resulting in a biradical pair. Further reaction path depends on the type of the halogen bonded and on the solvent polarity
Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders
申请人:Balestra Michael
公开号:US20090069340A1
公开(公告)日:2009-03-12
Compounds of Formula (I), wherein R
1
, R
2
, R
3
, R
4
, R
5
, R
6
, X, and n are as defined for Formula (I) in the description, processes for the preparation of the compounds and new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and the use of the compounds in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction.